Finance

Lists
Outlook: 73.7% bullish·0.0% bearish
Go to analysis
VERA:NASDAQ
Vera Therapeutics, Inc
$34.25
+0.74%
(+0.25) 1D
$34.25
0.00% (0.00)
After hours
Closed: Sep 21, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for VERA...
Open
$34.50
High
$34.98
Low
$33.65
Mkt. cap
2.47B
Avg. vol.
2.48M
Volume
1.23M
52-wk high
$56.05
52-wk low
$23.05
EPS
-$5.86
Beta
0.96
Shares outstanding
72.06M
No. of employees
361
Open
$34.50
High
$34.98
Low
$33.65
Mkt. cap
2.47B
Avg. vol.
2.48M
Volume
1.23M
52-wk high
$56.05
52-wk low
$23.05
EPS
-$5.86
Beta
0.96
Shares outstanding
72.06M
No. of employees
361
News stories
From web sources and news partners
About Vera Therapeutics, Inc
CEO-
Employees361
Founded2016
HeadquartersBrisbane, California, United States
SectorBiotechnology
Websiteveratx.com
Analyst ratings
Based on 12 analysts giving stock ratings to VERA in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for VERA in the last 3 months.
Highest
Current $34.25
$100.00 (+191.97%)
Average
$75.40 (+120.15%)
Lowest
$34.00 (-0.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Jefferies
Buy
Maintained
$59.00
+72.3%
09/16/2026
Laura Chico
Wedbush
Hold
Maintained
$34.00
-0.7%
09/16/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
-
-
09/15/2026
Dina Ramadane
Bank of America Securities
Buy
Reiterated
$66.00
+92.7%
09/15/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$70.00
+104.4%
09/15/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$90.00
+162.8%
09/15/2026
Ryan Deschner
Raymond James
Buy
Maintained
-
-
09/15/2026
Ritu Baral
TD Cowen
Buy
Maintained
$78.00
+127.7%
08/31/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$76.00
+121.9%
08/14/2026
Arthur He CFA
H.C. Wainwright
Buy
Reiterated
$90.00
+162.8%
08/12/2026
Pete Stavropoulos
Cantor Fitzgerald
Buy
Maintained
$100.00
+192%
08/10/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$91.00
+165.7%
07/09/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$70.00
+104.4%
06/11/2026
Paul Choi
Goldman Sachs
Buy
Maintained
$90.00
+162.8%
06/05/2026
Andy Chen
Wolfe Research
Buy
Maintained
$88.00
+156.9%
06/02/2026
Unknown Analyst
Wedbush
Hold
Maintained
$35.00
+2.2%
05/08/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
56.47M
59.31M
86.01M
60.08M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.46M
34.90M
39.12M
52.41M
Operating expense
83.93M
94.21M
125.13M
112.49M
Total operating expenses
83.93M
94.21M
125.13M
112.49M
Operating income
-83.93M
-94.21M
-125.13M
-112.49M
Other non operating income
-137.00K
-303.00K
-32.00K
-483.00K
EBT including unusual items
-80.29M
-91.10M
-121.03M
-109.47M
EBT excluding unusual items
-80.29M
-90.90M
-120.63M
-109.47M
Income tax expense
-
1.00K
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-80.29M
-91.10M
-121.03M
-109.47M
Net profit margin
-
-
-
-
Earnings per share
-1.26
-1.39
-1.69
-1.52
Interest and investment income
5.74M
5.52M
6.36M
5.35M
Interest expense
-1.96M
-1.90M
-1.82M
-1.85M
Net interest expenses
3.78M
3.61M
4.53M
3.50M
Depreciation and amortization charges
-
-
-
-
EBITDA
-83.80M
-94.07M
-124.99M
-112.36M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps